Please assess the completion status of the following clinical trial:

Trial Title: Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with a body mass index \>35 who have undergone cesarean delivery in the last 12 hours who will receive thromboprophylaxis with enoxaparin~* Subjects who consent to the study.~Exclusion Criteria:~* Women with a previous history of deep venous thrombosis or pulmonary embolism~* Women who are currently receiving another form of low molecular weight heparin or unfractionated heparin.~* Women who are receiving other concomitant anticoagulant medications, such as warfarin, lepirudin, or argatroban.~* Subjects who are unable or unwilling to give informed consent.~* Women who, in the judgment of the investigators, would not be in the best interest of the patient to participate in the study.~* Allergy to enoxaparin.~* Women with renal impairment~* Women with contraindications to Lovenox treatment such as women with active bleeding or thrombocytopenia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Enoxaparin Once Daily (Type: ACTIVE_COMPARATOR): This arm will have patients randomized to receive 40 mg sub-cutaneous injection of Lovenox (enoxaparin) once daily.
- Enoxaparin Twice Daily (Type: ACTIVE_COMPARATOR): This arm will have patients randomized to receive weight based (0.5 mg/kg) sub-cutaneous injection of Lovenox (enoxaparin) twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).